Cell size and growth are tightly regulated processes balancing synthesis and metabolism to ensure proper cell function. Deviations from normal growth in response to drug treatment provide insights into the induced cellular dysfunction caused by pharmacotherapy. These changes in biomass growth have shown promise as a marker for drug sensitivity. However, like many biomarkers, the output cannot be treated as binary. Just as cancer cells are heterogenous on the molecular level, individual cells’ biomass response to drug treatment can range from cell death to no effect. It is therefore important to begin to survey for the full range of biomass growth responses to drug treatment to understand the dysfunction induced. Here, we explore the response of different cancer cell lines to treatments that induce biomass growth changes ranging from apoptosis to senescence to simply delayed regrowth. These longer-term studies, ranging up to six days of constant monitoring, aid in the interpretation of more commonly performed shorter-term biomass growth experiments and identify cells of interest for further molecular characterization in these cell lines.
|